Navigation Links
Free Prostate Screenings Offered at Virginia G. Piper Cancer Center
Date:9/2/2010

SCOTTSDALE, Ariz., Sept. 2 /PRNewswire-USNewswire/ -- Recognizing that early detection can save lives, the Virginia G. Piper Cancer Center at Scottsdale Healthcare is offering free prostate cancer screenings from 8:30 a.m.-12 p.m. on Saturday, Sept. 11.

Urologists from Scottsdale Healthcare will be available to answer questions and talk about prostate cancer diagnosis and treatment options. Free prostate screenings include a Prostate Specific Antigen blood test and digital rectal exam.

The Virginia G. Piper Cancer Center at Scottsdale Healthcare is located at 10460 N. 92nd St. on the campus of Scottsdale Healthcare Shea Medical Center.

Appointments for the screening can be made by calling 480-882-4636.

  • Hear about prostate cancer diagnosis and treatment options at 8:30 a.m. and 10:45 a.m.
  • See nutrition and cooking demonstrations for prostate health at 9:30 a.m. and 10:30 a.m.
  • Adult flu shots will be available for $25.
  • Get 25% off at Tina's Treasures Boutique, dedicated to meeting the needs of cancer patients.

Attendees can take the controls of a daVinci robotic surgical system to experience the precision it offers in minimally invasive surgery. Arizona's first daVinci robot-assisted prostatectomy was performed by surgeons at Scottsdale Healthcare.

The daVinci is the world's leading surgical robot for minimally invasive procedures, which result in smaller incisions, less post-operative pain and faster recovery times. Scottsdale Healthcare has the longest experience with the daVinci robot of any Arizona hospital, acquiring the state's first daVinci in 2001.

Surgeons are now using three of the high-tech daVinci robots at Scottsdale Healthcare Thompson Peak Hospital and Scottsdale Healthcare Shea Medical Center. One of Scottsdale Healthcare's experienced daVinci surgeons will be on hand to answer questions about robotic surgery.

According to the American Cancer Society:

  • 1 in 6 men is at a lifetime risk of prostate cancer.
  • About 1 man in 36 will die of prostate cancer.
  • Almost 2 out of 3 prostate cancers are found in men over age 65.
  • Prostate cancer is the second leading cause of cancer death in American men.
  • Other than skin cancer, prostate cancer is the most common cancer in American men.

The Virginia G. Piper Cancer Center at Scottsdale Healthcare opened in 2001 as the first major cancer center in greater Phoenix, offering comprehensive cancer research, diagnosis, treatment, prevention and support services in a single location. The Commission on Cancer of the American College of Surgeons has awarded Accreditation with Commendation to the Scottsdale Healthcare cancer program.

Scottsdale Healthcare is the community-based, not-for-profit parent organization of the Scottsdale Healthcare Osborn Medical Center, Scottsdale Healthcare Shea Medical Center and Scottsdale Healthcare Thompson Peak Hospital, Virginia G. Piper Cancer Center at Scottsdale Healthcare, Scottsdale Healthcare Research Institute and Scottsdale Healthcare Foundation. A leader in medical innovation, talent and technology, Scottsdale Healthcare was founded in 1962 and is based in Scottsdale, Ariz. For more information, visit www.shc.org.


'/>"/>
SOURCE Scottsdale Healthcare
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
2. Use it or Lose it: A New Theory About Preserving Erectile Function After Prostate Surgery
3. Gene Fusion Subtypes in Prostate Carcinoma Have Clinical Implications
4. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
5. Peregrine Reports Data Showing Bavituximabs Potential to Shrink Prostate Tumors
6. Peregrine Researchers Report Data Showing Bavituximabs Potential to Shrink Human Prostate Tumors in Model of Relapsed Disease
7. Study Suggests Soy Protein May Reduce Prostate Cancer Risk
8. Dendreon Completes Target Enrollment of 500 Patients in Phase 3 IMPACT Study of Provenge(R) For Advanced Prostate Cancer
9. Medivations MDV3100 Demonstrates Substantial PSA Reductions in First Patient Groups Treated in Phase 1-2 Hormone Refractory Prostate Cancer Trial
10. Prostate Cancer Treatment Centre Receives Funding for Clinical Trials
11. Interim Analysis Supports Continuation of Cell Genesys VITAL-1 Phase 3 Clinical Trial of GVAX Immunotherapy for Prostate Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)...  Cogentix Medical, Inc. (NASDAQ: CGNT), a global ... Uro/Gyn and Gynecology markets with innovative and proprietary ... the Company as Senior Vice President, Marketing & ... Keswani will report directly to Darin Hammers ... is delighted that Ash has joined the Cogentix ...
(Date:4/20/2017)... Mass. , April 20, 2017  RXi ... developing innovative therapeutics that address significant unmet medical ... data from the Company,s consumer product development program, ... at the Society for Investigative Dermatology (SID) 76 ... to advance and promote the sciences relevant to ...
(Date:4/20/2017)... -- AbbVie (NYSE: ABBV), a global biopharmaceutical company, today ... C virus (HCV) infected patients with genotype 1, ... (Child-Pugh A) achieved sustained virologic response at 12 ... pan-genotypic regimen of glecaprevir/pibrentasvir (G/P). These high SVR ... of G/P treatment without ribavirin. Patients with specific ...
Breaking Medicine Technology:
(Date:4/21/2017)... Palm Beach, FL (PRWEB) , ... April 21, 2017 , ... The staff at Palm ... , will be taking part in the 2017 London Marathon. Set to take place on ... of charitable organizations. This year, Dr. Schwartz will run as part of team EMPOWER, raising ...
(Date:4/21/2017)... ... April 21, 2017 , ... Evoke Therapy Programs , ... kicked off its 4th annual Forum for Innovative Treatment Solutions (FITS), which runs ... Therapy for Mental Health and Addiction.” , FITS’ 2017 keynote presenters will ...
(Date:4/21/2017)... ... April 21, 2017 , ... Dudnyk has announced the launch of its new ... the full potential of specialty and orphan brands can only be achieved when the ... “The Unifying Effect is at the heart of a true partnership between our agency ...
(Date:4/21/2017)... ... 2017 , ... The VIA Agency , a full-service ... Theravent, Inc. , the makers of a revolutionary new device clinically proven to ... working to expand distribution in anticipation of a national launch. VIA will be ...
(Date:4/21/2017)... ... April 21, 2017 , ... ... campaign, AWARE: A Week of Addiction and Recovery Education, from April 24 to ... and preventing substance use disorders. , The mission of AWARE is to ...
Breaking Medicine News(10 mins):